Decoy Therapeutics Inc.: 10-Q filed 2023-05-11

Name: Decoy Therapeutics Inc.: 10-Q filed 2023-05-11
Creator: Decoy Therapeutics Inc.

What Decoy Therapeutics Inc. reported in its quarterly report filed 2023-05-11 (fiscal Q1 2023): 28 published measures, 60 facts as tagged in accession 0001615219-23-000038.

This filing

Form: 10-Q (quarterly report)
Filed: 2023-05-11
Fiscal period: fiscal Q1 2023
Accession: 0001615219-23-000038 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All Decoy Therapeutics Inc. filings.

Reported measures

Total assets

Resources recognized on the balance sheet. Book assets are not the market value of the business.

Period	Value	Unit	Days
At 2023-03-31	10,055,159	USD
At 2022-12-31	14,650,799	USD

Total liabilities

Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.

Period	Value	Unit	Days
At 2023-03-31	4,496,298	USD
At 2022-12-31	4,266,191	USD

Stockholders equity

The reported residual interest after liabilities. It is an accounting amount, not market capitalization.

Period	Value	Unit
At 2023-03-31	5,558,861	USD
At 2022-12-31	10,384,608	USD
At 2022-03-31	33,415,563	USD
At 2021-12-31	38,722,985	USD

Cash and cash equivalents

Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.

Period	Value	Unit	Days
At 2023-03-31	9,273,682	USD
At 2022-12-31	12,106,435	USD

Net income or loss

Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.

Period	Value	Unit	Days
2023-01-01 to 2023-03-31	-5,340,773	USD	90
2022-01-01 to 2022-03-31	-6,109,225	USD	90

Operating cash flow

Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.

Period	Value	Unit	Days
2023-01-01 to 2023-03-31	-3,169,435	USD	90
2022-01-01 to 2022-03-31	-3,520,826	USD	90

Contract revenue excluding tax

Revenue from customer contracts excluding assessed taxes under this specific taxonomy concept. It is not automatically comparable to older revenue tags.

Period	Value	Unit	Days
2023-01-01 to 2023-03-31	0	USD	90
2022-01-01 to 2022-03-31	0	USD	90

Financing cash flow

Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.

Period	Value	Unit	Days
2023-01-01 to 2023-03-31	336,682	USD	90
2022-01-01 to 2022-03-31	0	USD	90

Investing cash flow

Net cash from investing activities, including asset purchases, disposals and investment transactions. This differs from capital expenditure payments alone.

Period	Value	Unit	Days
2023-01-01 to 2023-03-31	0	USD	90
2022-01-01 to 2022-03-31	-1,500,000	USD	90

Retained earnings or deficit

Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.

Period	Value	Unit	Days
At 2023-03-31	-69,145,921	USD
At 2022-12-31	-63,805,148	USD

Basic weighted-average shares

Time-weighted shares used for basic earnings per share. This denominator differs from shares outstanding at a single reporting date.

Period	Value	Unit	Days
2023-01-01 to 2023-03-31	2,391,964	shares	90
2022-01-01 to 2022-03-31	1,850,208	shares	90

Diluted weighted-average shares

Weighted-average shares used for diluted earnings per share. Potential shares are included under the applicable dilution rules, not simply added to outstanding shares.

Period	Value	Unit	Days
2023-01-01 to 2023-03-31	2,391,964	shares	90
2022-01-01 to 2022-03-31	1,850,208	shares	90

Basic earnings per share

Reported earnings or loss per basic common share or unit. Inspect attribution, share classes and restatements before comparing periods. This is not a market return.

Period	Value	Unit	Days
2023-01-01 to 2023-03-31	-2.23	USD/shares	90
2022-01-01 to 2022-03-31	-3.3	USD/shares	90

Diluted earnings per share

Reported earnings or loss per share under dilution rules. Antidilutive instruments may be excluded. A diluted value can equal the basic value without implying no potential dilution.

Period	Value	Unit	Days
2023-01-01 to 2023-03-31	-2.23	USD/shares	90
2022-01-01 to 2022-03-31	-3.3	USD/shares	90

Share-based compensation expense

Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.

Period	Value	Unit	Days
2023-01-01 to 2023-03-31	203,345	USD	90
2022-01-01 to 2022-03-31	313,903	USD	90

Operating income or loss

Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.

Period	Value	Unit	Days
2023-01-01 to 2023-03-31	-5,420,663	USD	90
2022-01-01 to 2022-03-31	-6,117,229	USD	90

Current assets

Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.

Period	Value	Unit	Days
At 2023-03-31	9,940,307	USD
At 2022-12-31	14,520,298	USD

Current accounts payable

Current amounts owed to suppliers for goods and services received. This is one component of current liabilities, not all accrued obligations.

Period	Value	Unit	Days
At 2023-03-31	3,510,905	USD
At 2022-12-31	2,858,330	USD

Operating expenses

Recurring operating costs under this accounting concept, generally excluding production costs included in cost of sales. Check filing presentation before combining expense subtotals.

Period	Value	Unit	Days
2023-01-01 to 2023-03-31	5,420,663	USD	90
2022-01-01 to 2022-03-31	6,117,229	USD	90

Research and development expense

Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.

Period	Value	Unit	Days
2023-01-01 to 2023-03-31	3,725,588	USD	90
2022-01-01 to 2022-03-31	4,439,475	USD	90

Common shares outstanding

Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.

Period	Value	Unit	Days
At 2023-03-31	2,468,297	shares
At 2022-12-31	2,255,899	shares

Cash including restricted cash

Cash, cash equivalents and restricted cash as reported in the cash flow reconciliation. Restricted amounts are not freely available, so this is not the same as unrestricted cash.

Period	Value	Unit
At 2023-03-31	9,273,682	USD
At 2022-12-31	12,106,435	USD
At 2022-03-31	24,193,554	USD
At 2021-12-31	29,214,380	USD

Additional paid-in capital

Capital contributed above par value under this concept. It records historical contributions, not the current value of the equity or cash on hand.

Period	Value	Unit	Days
At 2023-03-31	74,704,536	USD
At 2022-12-31	74,189,531	USD

Other noncurrent assets

Noncurrent assets the filer does not present separately. The composition differs by filer and is described only in the filing.

Period	Value	Unit	Days
At 2023-03-31	114,852	USD
At 2022-12-31	130,501	USD

Prepaid expenses and other current assets

Prepayments and other current assets grouped under this concept. The balance is not cash and its composition differs by filer.

Period	Value	Unit	Days
At 2023-03-31	536,625	USD
At 2022-12-31	803,373	USD

General and administrative expense

General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.

Period	Value	Unit	Days
2023-01-01 to 2023-03-31	1,695,075	USD	90
2022-01-01 to 2022-03-31	1,677,754	USD	90

Depreciation, depletion and amortization

Combined depreciation, depletion and amortization for the period. A noncash allocation of asset cost, not a measure of maintenance spending.

Period	Value	Unit	Days
2023-01-01 to 2023-03-31	1,669	USD	90
2022-01-01 to 2022-03-31	4,797	USD	90

Change in accounts payable

The cash flow adjustment for the change in payables during the period. A positive value under this concept means payables grew and added to operating cash flow.

Period	Value	Unit	Days
2023-01-01 to 2023-03-31	627,576	USD	90
2022-01-01 to 2022-03-31	150,302	USD	90

Inspect the source

Entity: Decoy Therapeutics Inc. / CIK 0001615219
Captured: 2026-09-21T17:20:32.388Z
SEC response SHA-256: 3dae29679ef228e32bff301a79640d7e283fcc5b87c08a4882faedfce1c66e98

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python

import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001615219.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))